Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia

Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%

Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class…